These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12844464)

  • 21. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Discrepancy: Calcium Channel Blockers Are Effective for the Treatment of Hypertensive Left Ventricular Hypertrophy but Not as Effective for Prevention of Heart Failure.
    Koracevic G; Perisic Z; Stanojkovic M; Stojanovic M; Zdravkovic M; Tomasevic M; Djordjevic D; Mladenovic K; Koracevic M; Trkulja J
    Med Princ Pract; 2022; 31(5):454-462. PubMed ID: 36044874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J; Delpón E; Valenzuela C
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives.
    Cacciapuoti F
    J Am Soc Hypertens; 2011; 5(6):449-55. PubMed ID: 22015318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
    Unger T; Paulis L; Sica DA
    Eur Heart J; 2011 Nov; 32(22):2739-47. PubMed ID: 21951628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of Antihypertensive Drugs on Regression of Left Ventricular Hypertrophy].
    Koziolova NA; Shatunova IM
    Kardiologiia; 2015; 55(6):88-97. PubMed ID: 26625525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regression of left ventricular hypertrophy--are there differences between antihypertensive agents?
    Dahlöf B
    Cardiology; 1992; 81(4-5):307-15. PubMed ID: 1363788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of antihypertensive therapy: cardiac and extracardiac considerations.
    Messerli FH; Soria F
    Cardiology; 1992; 81(4-5):316-24. PubMed ID: 1301259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?
    Quintana-Villamandos B; Delgado-Baeza E
    Med Hypotheses; 2016 Feb; 87():44-7. PubMed ID: 26826640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of left ventricular hypertrophy: are there preferred drugs?
    Diamond JA; Phillips RA
    Curr Hypertens Rep; 2003 Oct; 5(5):368-71. PubMed ID: 12948428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.
    Kjeldsen SE; Strand A; Julius S; Okin PM
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):487-92. PubMed ID: 16849902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
    Yoshida C; Goda A; Naito Y; Nakaboh A; Matsumoto M; Otsuka M; Ohyanagi M; Hirotani S; Lee-Kawabata M; Tsujino T; Masuyama T
    J Hypertens; 2011 Feb; 29(2):357-63. PubMed ID: 21052021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic options in minimizing left ventricular hypertrophy.
    Devereux RB
    Am Heart J; 2000 Jan; 139(1 Pt 2):S9-14. PubMed ID: 10618582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ischaemia and left ventricular hypertrophy.
    Otterstad JE
    Eur Heart J; 1993 Oct; 14 Suppl F():2-6. PubMed ID: 7903244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology and clinical aspects of hypertensive hypertrophy.
    Vogt M; Motz WH; Schwartzkopf B; Strauer BE
    Eur Heart J; 1993 Jul; 14 Suppl D():2-7. PubMed ID: 8103741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.